Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S CETIRIZINE HYDROCHLORIDE HIVES RELIEF versus CLARITIN REDITABS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S CETIRIZINE HYDROCHLORIDE HIVES RELIEF versus CLARITIN REDITABS.
CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF vs CLARITIN REDITABS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cetirizine is a selective histamine H1-receptor antagonist. It inhibits the H1 receptor, reducing histamine-mediated effects such as edema, flare, and pruritus.
Loratadine is a selective antagonist of peripheral histamine H1 receptors, reducing allergic response symptoms by inhibiting histamine release from mast cells.
5 mg or 10 mg orally once daily; maximum 10 mg per day.
10 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life is approximately 8.3 hours in healthy adults; prolonged to ~20 hours in renal impairment (CrCl <30 mL/min).
Terminal elimination half-life: 8–28 hours (mean ~14 hours for loratadine; active metabolite desloratadine: 14–26 hours). Context: Allows once-daily dosing; half-life extended in hepatic impairment.
Approximately 70% of the dose is excreted unchanged in urine via glomerular filtration and tubular secretion; about 10% is eliminated in feces.
Renal (approximately 40% as metabolites) and fecal (approximately 40% as metabolites). Parent drug and active metabolite (desloratadine) are excreted in urine (27% total) and feces (40% total).
Category A/B
Category C
Antihistamine
Antihistamine